NantKwest, Inc. (NK) News
Filter NK News Items
NK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NK News Highlights
- NK's 30 day story count now stands at 5.
- Over the past 17 days, the trend for NK's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about NK are GS, RL and III.
Latest NK News From Around the Web
Below are the latest news stories about NantKwest Inc that investors may wish to consider to help them evaluate NK as an investment opportunity.
ImmunityBio and NantKwest Complete MergerImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. ("ImmunityBio") and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker "IBRX." |
NantKwest's Charts Are Extended When Compared to the Popular Moving AveragesDuring Friday's "Lightning Round" segment of Mad Money, one caller quizzed Jim Cramer about NantKwest . In this daily bar chart of NK, below, we can see that prices made a base down in the $5 area before rallying in December and soaring into February. NK is trading above the rising 50-day moving average line and is extended (overbought) when compared to the rising 200-day line which intersects down at only $12. |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWHHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger InvestigationWILMINGTON, Del., Feb. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: NantKwest, Inc. (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest’s agreement to merge with ImmunityBio, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-nantkwest-inc. Cardtronics plc (NASDAQ GS: CATM) regarding possible breaches of fiduciary duties and other violations of law related to Cardtronics’ agreement to be acquired by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cardtronics-plc. Landcadia Holdings III, Inc. (NASDAQ GS: LCYAU) regardin... |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates AEGN, FFG, NK, GWPH; Shareholders Are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / February 20, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:Aegion Corporation (NASDAQ:AEGN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to affiliates of New Mountain Capital, L. If you are an Aegion shareholder, click here to learn more about your rights and options. |
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody ImmunityImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA also authorized a second Phase I study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials of their vaccine candidate, which is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 v... |
What Kind Of Investors Own Most Of NantKwest, Inc. (NASDAQ:NK)?Every investor in NantKwest, Inc. ( NASDAQ:NK ) should be aware of the most powerful shareholder groups. Large... |
RM LAW Announces Investigation of NantKwest, Inc.BERWYN, Pa. , Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK ) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to ImmunityBio, Inc. If … Full story available on Benzinga.com |
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual J.P. Morgan Healthcare Conference. He will make a formal presentation and answer questions at 5:20 a.m. Pacific Time (8:20 a.m. Eastern Time) on Wednesday, January 13, 2021. Dr. Soon-Shiong will discuss NantKwest’s previously announc |
NantKwest Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysisNantKwest announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by… |